Abstract Lessons Learned The combination of anlotinib and S-1 exhibited good antitumor
activity in third-or later-line treatment for stage IV non-small cell lung cancer (NSCLC) …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

There is no standard treatment strategy for the third-line and above treatment of advanced
nonsmall cell lung cancer (NSCLC). This study aimed to investigate the effects of anlotinib in …

Background Anlotinib (AL3818) is a novel multi-target angioenesis TKI targeting the VEGFR,
FGFR, PDGFR and c-Kit. In the ALTER0303 trial, Anlotinib as third-line treatment …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit
both tumor angiogenesis and signal transduction pathways associated with proliferation …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Aim: The aim of this randomised, double-blind, placebo-controlled, anlotinb study was to
investigate its efficacy and safety in patients with refractory non-small-cell lung cancer …

Background Anlotinib hydrochloride, a novel multi-targeted tyrosine kinase inhibitor (TKI)
was found to exhibit excellent inhibitory efficiency on a variety of receptor tyrosine kinases …